Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • Bill Pay Log In Required
    • Bill Pay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Tax Forms & Information
    • Retirement Distributions Log In Required
    • Fidelity Rewards+ Log In Required
    • New Account Checklist Log In Required
  • Planning & Advice
    • What We Offer
    • My Goals
    • Financial Basics
    • Building Savings
    • Robo Investing Plus Financial Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
  • News & Research
    • News
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Trading
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sector Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Account
    • Annuities
    • Life Insurance & Long Term Care
    • Charitable Giving
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


Find Symbol. Opens in new window.
  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Bluebird to spin off cancer drugs unit to focus on genetic diseases

BY Reuters
— 6:58 AM ET 01/11/2021

By Manojna Maddipatla

Jan 11 (Reuters) - Bluebird bio Inc (BLUE) said on Monday it plans to spin off its cancer drugs unit into a new, publicly traded company later this year to focus on rare genetic diseases.

The gene therapy developer suffered multiple regulatory setbacks last year for both its rare disease and cancer drug candidates. Splitting the company removes the diversification it has with having both cancer cell therapies and gene therapy programs, said J.P.Morgan analyst Cory Kasimov in a client note.

The split is an interesting strategic development, but how it plays out is largely to be determined, Kasimov said.

Shares of the company were down about 3% in early morning trading.

Gene therapies, which aim to potentially cure patients of life-threatening diseases, have attracted hefty investments from drug developers in recent years - but are expensive.

In November, the submission of a marketing application for bluebird's blood disorder gene therapy, LentiGlobin, was pushed to 2022 from 2021 after the U.S. Food and Drug Administration set additional requirements.

LentiGlobin or Zynteglo is approved in Europe for treating beta thalassemia and is priced there at 1.58 million euros ($1.92 million) over five years.

The slimmer bluebird aims to expand access to Zynteglo in Europe and build on its gene therapy manufacturing expertise, the company said, which expects the separation to close in the fourth quarter.

Chief Executive Officer Nick Leschly will helm the new cancer company and take up a new role as executive chair of bluebird bio.

The president of bluebird bio's severe genetic diseases business, Andrew Obenshain, will become its CEO.

The company and partner Bristol Myers Squibb Co also suffered a regulatory setback for their multiple myeloma therapy, ide-cel, last May. The drug still awaits the FDA's decision by March.

On Monday, the Wall Street Journal first reported the move and said Leschly had cited the need for increased specialization as the reason for the split. ($1 = 0.8223 euros) (Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel, Bernard Orr)

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More BLUE News

BLUE has no more news
Fidelity Investments. Copyright 1998–2021 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close